Delaware will receive $2-million from Johnson & Johnson as part of a national settlement that will resolve allegations that the pharmaceutical company fraudulently marketed two anti-psychotic drugs. The AG’s Medicaid Fraud Control Unit secured $943,821 in civil restitution and fines for the Delaware Medicaid & Medical Assistance program. The litigation has been ongoing since 2008. Nationally Johnson & Johnson will pay state and federal governments $1.2-billion over charges that Risperdal and Invega were promoted and marketed for uses not approved by the FDA and for uses not medically indicated.
Additionally – legislation approved by the Delaware General Assembly will bring Delaware a 10% bonus in its share of future settlements in similar cases under the Delaware False Claims & Reporting Act which is expected to bring hundreds of thousands of dollars in recoveries for Delaware and the Delaware Medicaid & Medical Assistance program.
In the same case - Maryland will receive over $20-million from the $1.2-billion settlement.
Return to: WGMD Local News Blog